CA3204344A1 - Treatment of hemophilia with fitusiran - Google Patents

Treatment of hemophilia with fitusiran

Info

Publication number
CA3204344A1
CA3204344A1 CA3204344A CA3204344A CA3204344A1 CA 3204344 A1 CA3204344 A1 CA 3204344A1 CA 3204344 A CA3204344 A CA 3204344A CA 3204344 A CA3204344 A CA 3204344A CA 3204344 A1 CA3204344 A1 CA 3204344A1
Authority
CA
Canada
Prior art keywords
fitusiran
patient
level
patients
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204344A
Other languages
English (en)
French (fr)
Inventor
Stacey POLOSKEY
Shauna Andersson
Pratik R. BHAGUNDE
Yue CUI
Sajida IQBAL
Baisong Mei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3204344A1 publication Critical patent/CA3204344A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3204344A 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran Pending CA3204344A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063121973P 2020-12-06 2020-12-06
US63/121,973 2020-12-06
US202163272629P 2021-10-27 2021-10-27
US63/272,629 2021-10-27
US202163275344P 2021-11-03 2021-11-03
US63/275,344 2021-11-03
PCT/US2021/062078 WO2022120292A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Publications (1)

Publication Number Publication Date
CA3204344A1 true CA3204344A1 (en) 2022-06-09

Family

ID=80112089

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204344A Pending CA3204344A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Country Status (10)

Country Link
US (1) US20240027478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552554A (cg-RX-API-DMAC7.html)
KR (1) KR20230117403A (cg-RX-API-DMAC7.html)
AU (1) AU2021391951A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204344A1 (cg-RX-API-DMAC7.html)
IL (1) IL303452A (cg-RX-API-DMAC7.html)
MX (1) MX2023006651A (cg-RX-API-DMAC7.html)
TW (1) TW202237151A (cg-RX-API-DMAC7.html)
WO (1) WO2022120292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258425A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
EP4612687A1 (en) 2022-11-02 2025-09-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin
TW202525306A (zh) * 2023-09-15 2025-07-01 美商健臻公司 用非妥西蘭(fitusiran)治療a型血友病
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Also Published As

Publication number Publication date
TW202237151A (zh) 2022-10-01
EP4255566A1 (en) 2023-10-11
JP2023552554A (ja) 2023-12-18
US20240027478A1 (en) 2024-01-25
AU2021391951A1 (en) 2023-07-20
IL303452A (en) 2023-08-01
KR20230117403A (ko) 2023-08-08
AU2021391951A9 (en) 2024-05-02
MX2023006651A (es) 2023-08-02
WO2022120292A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US20240027478A1 (en) Treatment of hemophilia with fitusiran
US20240230644A1 (en) Methods of treating transthyretin (ttr) mediated amyloidosis
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
US20260014188A1 (en) Methods and compositions for treating hemophilia
US20240189394A1 (en) Methods of using and compositions containing dulaglutide
JP2025519491A (ja) 小児患者における血友病a及びbの処置のためのフィツシラン
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
EP3833381B1 (en) Modified factor vii polypeptides for subcutaneous administration
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
CN116635040A (zh) 用非妥西兰治疗血友病
EP3581196A1 (de) Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von erkrankungen des knochens, des eisenstoffswechsels und der blutbildung
HK40056298A (en) Modified factor vii polypeptides for subcutaneous administration

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241031

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202